Adrian Hayday, trained in biochemistry at Cambridge, and began studying immunology in 1982 at MIT, where he and his colleagues first described the wholly unanticipated T cell receptor gamma chain genes. After thirteen years on the Yale faculty, where he won the William Clyde deVane Medal, Yale College’s highest honour for scholarship and teaching, Professor Hayday returned to London, in part to place greater emphasis on clinical studies. Professor Hayday’s laboratory has established many criteria by which gamma-delta T cell biology appears unique, including the cells’ rapid responses to tissue local dysregulation. His finding that gamma-delta T cell deficiency confers susceptibility to carcinogens fueled many clinical studies, and led most recently to the founding of GammaDelta Therapeutics. Professor Hayday’s focus on immunogenetic approaches has led to the identification of Butyrophilin-like genes as conserved, tissue-specific gamma-delta T cell regulators; to the development of an open-access immunophenotyping portal of hundreds of gene knockout mouse strains, www.immunophenotype.org; and new insights into autoimmune disease derived from rare patient cohorts with defects in central tolerance. Professor Hayday was elected to lead the British Society of Immunology, and to be a fellow of the Academy of Medical Sciences and of the Royal Society.
« Go Back